Genovis Investor Relations » Press Releases

October 17, 2025 08:30 (CEST) Genovis receives order worth approximately 1 million euros from global pharmaceutical company Regulatory MAR

August 12, 2025 08:00 (CEST) Genovis AB Half-Yearly report January – June 2025 Regulatory MAR

July 24, 2025 08:30 (CEST) Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development

July 01, 2025 18:00 (CEST) Genovis Exercises Call Option to Acquire Remaining Shares in SEQURNA, a fast-growing next-generation RNase inhibitors company Regulatory MAR

May 21, 2025 18:50 (CEST) Communiqué from Genovis AB (publ) Annual General Meeting May 21, 2025 Regulatory

May 21, 2025 15:00 (CEST) Genovis AB Interim report January – March 2025 Regulatory MAR

April 28, 2025 08:00 (CEST) Genovis AB publishes Annual Report 2024 Regulatory

April 15, 2025 09:00 (CEST) NOTICE OF ANNUAL GENERAL MEETING OF GENOVIS AB (PUBL) Regulatory

February 14, 2025 08:00 (CET) Strong momentum: 21% growth in enzyme business and significant improvement in earnings Regulatory MAR

November 08, 2024 08:00 (CET) Genovis AB: Interim Report January-September 2024 Regulatory MAR

Press Releases